Johnson & Johnson (NYSE:JNJ) Holdings Raised by First Financial Bank Trust Division

First Financial Bank Trust Division increased its stake in Johnson & Johnson (NYSE:JNJ) by 1.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 62,803 shares of the company’s stock after purchasing an additional 779 shares during the quarter. Johnson & Johnson makes up 0.9% of First Financial Bank Trust Division’s investment portfolio, making the stock its 27th largest holding. First Financial Bank Trust Division’s holdings in Johnson & Johnson were worth $10,178,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Mattson Financial Services LLC acquired a new position in shares of Johnson & Johnson in the second quarter worth about $3,407,000. Ashburton Jersey Ltd acquired a new position in Johnson & Johnson in the 2nd quarter worth approximately $8,771,000. Clifford Capital Partners LLC grew its position in Johnson & Johnson by 53.5% during the 2nd quarter. Clifford Capital Partners LLC now owns 101,809 shares of the company’s stock worth $14,880,000 after purchasing an additional 35,481 shares in the last quarter. University of Texas Texas AM Investment Management Co. raised its stake in Johnson & Johnson by 16.3% during the 2nd quarter. University of Texas Texas AM Investment Management Co. now owns 21,979 shares of the company’s stock valued at $3,212,000 after purchasing an additional 3,087 shares during the period. Finally, Verity & Verity LLC lifted its holdings in shares of Johnson & Johnson by 8.6% in the second quarter. Verity & Verity LLC now owns 89,227 shares of the company’s stock valued at $13,041,000 after purchasing an additional 7,032 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of a number of research analyst reports. TD Cowen lowered their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, July 18th. TD Securities dropped their target price on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Sanford C. Bernstein increased their price target on shares of Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research report on Friday, September 20th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Trading Down 0.5 %

Johnson & Johnson stock opened at $161.17 on Thursday. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The company’s fifty day moving average price is $162.60 and its two-hundred day moving average price is $154.26. The company has a market capitalization of $387.88 billion, a price-to-earnings ratio of 10.05, a PEG ratio of 2.69 and a beta of 0.53. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The business had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm’s revenue was up 4.3% compared to the same quarter last year. During the same period last year, the business earned $2.80 EPS. On average, analysts forecast that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.08%. The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.